• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TRIMIPRAMINE Drug Record

  • Summary
  • Interactions
  • Claims
  • TRIMIPRAMINE chembl:CHEMBL644 Approved

    Alternate Names:

    IL-6001
    TRIMIPRAMINE
    SURMONTIL
    7162-RP
    TRIMEPROPRIMINE
    7162 RP
    SAPILENT
    TRIMEPRIMINE
    RP-7162
    5-(GAMMA-DIMETHYLAMINO-BETA-METHYLPROPYL)-10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPINE
    5-[3-(DIMETHYLAMINO)-2-METHYLPROPYL]-10,11-DIHYDRO-5H-DIBENZ[B,F]AZEPINE
    10,11-DIHYDRO-N,N,BETA-TRIMETHYL-5H-DIBENZ[B,F]AZEPINE-5-PROPANAMINE
    BETA-METHYLIMIPRAMINE
    SURMONTIL®
    chemidplus:739-71-9
    rxcui:10834
    drugbank:00726
    chembl:CHEMBL644
    pubchem.compound:5584

    Drug Info:

    Drug Class antidepressive agents, tricyclic
    Year of Approval 1979
    FDA Approval 1979
    Drug Class small molecule
    Drug Indications Antidepressive Agents, Tricyclic
    (3 More Sources)

    Publications:

    Leathart JB et al., 1998, CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles., Pharmacogenetics
    Dalén P et al., 1998, 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes., Clin Pharmacol Ther
    Dahl ML et al., 1996, Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype., Psychopharmacology (Berl)
    Nielsen KK et al., 1994, Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms., Clin Pharmacol Ther
    Hicks JK et al., 2013, Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants., Clin Pharmacol Ther
    de Vos A et al., 2011, Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients., Pharmacogenomics J
    Forget P et al., 2008, Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study., J Pain Symptom Manage
    Koski A et al., 2007, A fatal doxepin poisoning associated with a defective CYP2D6 genotype., Am J Forensic Med Pathol
    Schenk PW et al., 2008, Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients., Mol Psychiatry
    Johnson M et al., 2006, A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment., CNS Spectr
    Stephan PL et al., 2006, Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity., Pharmacopsychiatry
    Goetz MP et al., 2005, Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes., J Clin Oncol
    Koski A et al., 2006, CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies., Forensic Sci Int
    Tacke U et al., 1992, Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations., J Clin Psychopharmacol
    Vandel P et al., 2004, Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients., Hum Psychopharmacol
    Steimer W et al., 2004, Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers., Clin Chem
    Furman KD et al., 2004, Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics., Pharmacogenetics
    Roberts RL et al., 2004, No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline., Hum Psychopharmacol
    Kirchheiner J et al., 2003, Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity., Pharmacogenetics
    Kirchheiner J et al., 2003, Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics., J Clin Psychopharmacol
    Dahl ML et al., 1992, Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population., Clin Pharmacol Ther
    Kirchheiner J et al., 2002, Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers., Pharmacogenetics
    Murphy GM Jr et al., 2001, CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression., Neuropsychopharmacology
    Eap CB et al., 2000, Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients., Ther Drug Monit
    1999, Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Danish University Antidepressant Group (DUAG)., Clin Pharmacol Ther
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
    Haenisch B et al., 2011, Inhibitory potencies of trimipramine and its main metabolites at human monoamine and organic cation transporters., Psychopharmacology (Berl)
    Diamond et al., 2006, Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade., Eur Neuropsychopharmacol
    Berger et al., 1996, Trimipramine: a challenge to current concepts on antidepressives., Eur Arch Psychiatry Clin Neurosci
    Wang JH et al., 2001, Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19., Clin Pharmacol Ther
    Morinobu S et al., 1997, Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy., Psychiatry Clin Neurosci
    Koyama E et al., 1996, Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients., J Clin Psychopharmacol
    Brøsen K et al., 1995, A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype., Pharmacogenetics
    de Morais SM et al., 1994, The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans., J Biol Chem
    De Morais SM et al., 1994, Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese., Mol Pharmacol
    Swen JJ et al., 2011, Pharmacogenetics: from bench to byte--an update of guidelines., Clin Pharmacol Ther
    Sibbing D et al., 2010, Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy., J Thromb Haemost
    Sibbing D et al., 2010, Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement., Circulation
    Schenk PW et al., 2010, The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients., Pharmacogenomics J
    Rudberg I et al., 2008, Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients., Eur J Clin Pharmacol
    Rudberg I et al., 2008, Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients., Clin Pharmacol Ther
    Sim SC et al., 2006, A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants., Clin Pharmacol Ther
    Grasmäder K et al., 2004, Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting., Eur J Clin Pharmacol
    Desta Z et al., 2002, Clinical significance of the cytochrome P450 2C19 genetic polymorphism., Clin Pharmacokinet
  • TRIMIPRAMINE   SLC6A2

    Interaction Score: 1.36

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    17016423 17139284 9537821 21484238


    Sources:
    TdgClinicalTrial TEND

  • TRIMIPRAMINE   SLC6A4

    Interaction Score: 0.68

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    9537821 16388933


    Sources:
    TdgClinicalTrial TEND

  • TRIMIPRAMINE   CYP2D6

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9918137 9585799 8867869 8181196 23486447 20531370 18359183 17721180 17667959 17008819 16871470 16361630 16024198 1527229 15252821 15205367 15115913 14716707 14646691 14520122 1346258 12360109 11682257 10774635 10460069


    Sources:
    PharmGKB FDA

  • TRIMIPRAMINE   CYP2C19

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23486447 14520122 11452243 10774635 9316174 8835703 8563772 8195181 7969038 21412232 20531370 20492469 20083681 19884907 18677622 17625515 16413245 15168101 12222994


    Sources:
    PharmGKB

  • TRIMIPRAMINE   DRD1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    8863001


    Sources:
    DTC

  • TRIMIPRAMINE   CBX1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIMIPRAMINE   CYP2C9

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14520122


    Sources:
    PharmGKB

  • TdgClinicalTrial: TRIMIPRAMINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antidepressive Agents, Tricyclic
    Drug Class small molecule
    FDA Approval 1979

    Publications:

  • TEND: TRIMIPRAMINE

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Year of Approval 1979
    Drug Class antidepressive agents, tricyclic

    Publications:

  • PharmGKB: trimipramine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Rudberg I et al., 2008, Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients., Eur J Clin Pharmacol
    de Vos A et al., 2011, Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients., Pharmacogenomics J
    Brøsen K et al., 1995, A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype., Pharmacogenetics

  • DTC: TRIMIPRAMINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL644 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Trimipramine

    • Version: 2020.06.01

    Alternate Names:
    D00HZV TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL644

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Trimipramine

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21